Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of anti-Ly6E exatecan ADC M7437 in advanced solid tumors
jRCT2031250678Phase 1Recruiting
- Sponsor
- Merck KGaA
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of M7437 in non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC) and 4 more (2 cohorts), sponsored by Merck KGaA. Primary endpoints: Dose-escalation Cohort: Dose-limiting toxicities and Dose-escalation Cohort: Treatment-emergent adverse events and adverse events. Started Jan 2026; status: recruiting.
02
Drugs
M7437
03
Conditions
non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)pancreatic adenocarcinoma (PDAC)gastric cancer (GC)
Beyond the preview
Go deeper on jRCT2031250678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250678.